MX2009008408A - Diagnosis y tratamiento de preeclampsia. - Google Patents

Diagnosis y tratamiento de preeclampsia.

Info

Publication number
MX2009008408A
MX2009008408A MX2009008408A MX2009008408A MX2009008408A MX 2009008408 A MX2009008408 A MX 2009008408A MX 2009008408 A MX2009008408 A MX 2009008408A MX 2009008408 A MX2009008408 A MX 2009008408A MX 2009008408 A MX2009008408 A MX 2009008408A
Authority
MX
Mexico
Prior art keywords
preeclampsia
diagnosis
relates
treatment
disease
Prior art date
Application number
MX2009008408A
Other languages
English (en)
Inventor
Stefan Hansson
Bo Aakerstroem
Original Assignee
Stefan Hansson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stefan Hansson filed Critical Stefan Hansson
Publication of MX2009008408A publication Critical patent/MX2009008408A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99003—Heme oxygenase (1.14.99.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)

Abstract

La presente invención se refiere a biomarcadores para preeclampsia así como tratamientos de esta enfermedad. En particular, la invención se refiere a métodos para diagnosis o ayuda en la diagnosis de preeclampsia de un mamífero hembra preñado para detectar niveles elevados de hemoglobina libre, particularmente hemoglobina fetal libre. Esto facilita y hace posible la diagnosis temprana y la intervención clínica temprana cuando se encuentra una condición preeclámptica. Además, la invención se refiere a un método para tratar mamíferos hembra con preeclampsia con el propósito de invertir las condiciones patológicas asociadas con esta enfermedad.
MX2009008408A 2007-02-12 2008-02-12 Diagnosis y tratamiento de preeclampsia. MX2009008408A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0700339 2007-02-12
PCT/EP2008/001051 WO2008098734A1 (en) 2007-02-12 2008-02-12 Diagnosis and treatment of preeclampsia

Publications (1)

Publication Number Publication Date
MX2009008408A true MX2009008408A (es) 2009-11-02

Family

ID=39295873

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009008408A MX2009008408A (es) 2007-02-12 2008-02-12 Diagnosis y tratamiento de preeclampsia.
MX2013001577A MX347788B (es) 2007-02-12 2008-02-12 Diagnosis y tratamiento de preeclampsia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013001577A MX347788B (es) 2007-02-12 2008-02-12 Diagnosis y tratamiento de preeclampsia.

Country Status (18)

Country Link
US (3) US8568999B2 (es)
EP (3) EP2111555B1 (es)
JP (2) JP5604111B2 (es)
KR (2) KR101608501B1 (es)
AU (1) AU2008214837B2 (es)
BR (1) BRPI0808340A2 (es)
CA (1) CA2674204C (es)
DK (2) DK2614832T3 (es)
EA (2) EA031877B1 (es)
ES (2) ES2599003T3 (es)
HR (2) HRP20130809T1 (es)
HU (1) HUE031613T2 (es)
MX (2) MX2009008408A (es)
NZ (1) NZ578077A (es)
PL (2) PL2614832T3 (es)
PT (2) PT2111555E (es)
WO (1) WO2008098734A1 (es)
ZA (1) ZA200905101B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008214837B2 (en) * 2007-02-12 2013-01-10 A1M Pharma Ab Diagnosis and treatment of preeclampsia
EP2313106B1 (en) * 2008-07-18 2016-03-30 A1M Pharma AB Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
WO2011095981A1 (en) * 2010-02-03 2011-08-11 St. John's Research Institute An in-vitro method for characterizing hemoglobin variant
PT2550535E (pt) * 2010-03-24 2015-09-07 Preelumina Diagnostics Ab Hbf e a1m como marcadores de fase inicial para pré- eclâmpsia
CN103069277B (zh) * 2010-03-31 2016-03-30 积水医疗株式会社 利用免疫色谱法的测定法、免疫色谱测试条和用于免疫色谱法的测定试剂盒
CA2886489A1 (en) 2011-10-14 2013-04-18 Aarhus Universitet Diagnostic and prognostic use of prombp-complexes
CA2881321A1 (en) * 2012-09-05 2014-03-13 A1M Pharma Ab Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
US10928402B2 (en) 2012-12-28 2021-02-23 Nx Prenatal Inc. Treatment of spontaneous preterm birth
US20140186332A1 (en) * 2012-12-28 2014-07-03 NX Pharmagen Biomarkers of preterm birth
MX2017011198A (es) 2015-03-16 2018-02-19 A1M Pharma Ab Biomarcadores para preeclampsia.
KR101732933B1 (ko) 2015-07-29 2017-05-08 영남대학교 산학협력단 신생아의 성장 또는 심혈관계 질환 예후 진단 방법
JP2019505815A (ja) 2015-12-04 2019-02-28 エヌエックス・プリネイタル・インコーポレイテッドＮＸ Ｐｒｅｎａｔａｌ Ｉｎｃ． 自然早産リスクを層別化するための循環マイクロ粒子の使用
ES2969882T3 (es) 2018-03-19 2024-05-23 Regeneron Pharma Ensayos y reactivos de electroforesis capilar en microchip
US11418353B2 (en) * 2019-08-26 2022-08-16 Micron Technology, Inc. Security descriptor generation
CN111626280B (zh) * 2020-04-13 2021-09-07 北京邮电大学 一种无定位点答题卡识别方法和装置
WO2024053586A1 (ja) * 2022-09-05 2024-03-14 栄研化学株式会社 遊離ヘモグロビン測定試薬、遊離ヘモグロビン測定方法および抗ヘモグロビン抗体

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1337778A1 (ru) 1984-06-25 1987-09-15 Новосибирский государственный медицинский институт Способ диагностики т жести позднего токсикоза беременных
US5079171A (en) 1988-09-15 1992-01-07 Adeza Biomedical Corporation Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin
US5238819A (en) 1988-12-14 1993-08-24 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5108898A (en) 1989-01-18 1992-04-28 Peters John H Use of fibronectin having a variable included type III repeat sequence as a marker for toxemia in pregnancy
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
US6103691A (en) 1994-03-23 2000-08-15 Tschesche; Harald Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins
US5849474A (en) * 1995-12-06 1998-12-15 Olson; Camilla M. Diagnosis of preeclampsia in mammals
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6169816B1 (en) * 1997-05-14 2001-01-02 Applied Imaging, Inc. Identification of objects of interest using multiple illumination schemes and finding overlap of features in corresponding multiple images
JP2001348342A (ja) 2001-04-12 2001-12-18 Nippon Zoki Pharmaceut Co Ltd 免疫調整・抗炎症剤
ATE439588T1 (de) 2001-05-04 2009-08-15 Biosite Inc Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
DE60219642T2 (de) 2001-09-04 2008-01-17 Iq Corp. B.V. Bestimung und quantifizierung von erythrocytenpopulation in proben
JPWO2003083479A1 (ja) * 2002-03-29 2005-08-04 松下電器産業株式会社 血液処理方法、血液処理デバイス、ヘモグロビン類測定方法およびヘモグロビン類測定デバイス
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
EP1638605B1 (en) * 2003-06-20 2014-01-08 Raptor Pharmaceutical, Inc. Delivery of therapeutic compounds to the brain and other tissues
AR045074A1 (es) 2003-07-23 2005-10-12 Applied Research Systems Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
CA2547124A1 (en) * 2003-11-26 2005-06-09 Sanofi-Aventis Deutschland Gmbh Tubular proteinuria as an indicator for elevated cardiovascular risk
WO2005093413A2 (en) 2004-03-22 2005-10-06 Yale University Diagnosis and treatment of preeclampsia
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
GB0600916D0 (en) 2006-01-17 2006-02-22 Perkinelmer Instr Las Inc detecting and predicting pre-eclampsia
CA2636353A1 (en) * 2006-01-18 2007-07-26 Georg Wick Test systems for the analysis of polypeptides and cells adhering to silicones
AU2008214837B2 (en) 2007-02-12 2013-01-10 A1M Pharma Ab Diagnosis and treatment of preeclampsia
WO2009108073A1 (en) 2008-02-28 2009-09-03 Auckland Uniservices Limited Biomarkers for prediction of preeclampsia and/or cardiovascular disease
EP2313106B1 (en) 2008-07-18 2016-03-30 A1M Pharma AB Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
PT2550535E (pt) 2010-03-24 2015-09-07 Preelumina Diagnostics Ab Hbf e a1m como marcadores de fase inicial para pré- eclâmpsia

Also Published As

Publication number Publication date
ES2426069T3 (es) 2013-10-21
BRPI0808340A2 (pt) 2017-05-30
MX347788B (es) 2017-05-12
EA201500335A1 (ru) 2016-08-31
EA022609B1 (ru) 2016-02-29
DK2614832T3 (da) 2016-10-31
US20100105070A1 (en) 2010-04-29
KR20140095572A (ko) 2014-08-01
JP5604111B2 (ja) 2014-10-08
ES2599003T3 (es) 2017-01-31
PT2614832T (pt) 2016-10-18
US20140065170A1 (en) 2014-03-06
EP2111555B1 (en) 2013-05-29
AU2008214837B2 (en) 2013-01-10
JP2010518386A (ja) 2010-05-27
US8568999B2 (en) 2013-10-29
HRP20130809T1 (en) 2013-10-11
DK2111555T3 (da) 2013-09-02
KR101454013B1 (ko) 2014-11-12
EP2111555A1 (en) 2009-10-28
JP2014012670A (ja) 2014-01-23
HRP20161266T1 (hr) 2016-12-16
PT2111555E (pt) 2013-09-04
PL2614832T3 (pl) 2017-01-31
AU2008214837A1 (en) 2008-08-21
KR101608501B1 (ko) 2016-04-04
US10359406B2 (en) 2019-07-23
CA2674204C (en) 2017-07-11
EA031877B1 (ru) 2019-03-29
KR20100015315A (ko) 2010-02-12
NZ578077A (en) 2012-04-27
HUE031613T2 (en) 2017-09-28
EP2613150A1 (en) 2013-07-10
PL2111555T3 (pl) 2013-10-31
ZA200905101B (en) 2012-01-25
WO2008098734A1 (en) 2008-08-21
EA200970758A1 (ru) 2010-02-26
JP5792772B2 (ja) 2015-10-14
CA2674204A1 (en) 2008-08-21
EP2614832A1 (en) 2013-07-17
EP2614832B1 (en) 2016-07-13
US20180284087A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
MX2009008408A (es) Diagnosis y tratamiento de preeclampsia.
WO2014036440A3 (en) Papp-a2 as a marker for monitoring, predicting and diagnosing preeclampsia
WO2011092592A3 (en) Methods and compositions for noninvasive prenatal diagnosis of fetal aneuploidies
WO2014193999A3 (en) Biomarker methods and compositions
WO2013022995A3 (en) Biomarker compositions and methods
GB2463401B (en) Characterizing prostate disorders by analysis of microvesicles
WO2009009769A3 (en) Diagnosis of fetal abnormalities using nucleated red blood cells
GB2483810B (en) Methods for correlating clonotypes with diseases in a population
TW200730138A (en) Image analysis methods for gleno-humeral joint morphology
WO2009025852A3 (en) Methods of using mirna for detection of in vivo cell death
WO2007067719A3 (en) Diagnosing human diseases by detecting dna methylation changes
UA101167C2 (ru) Фармацевтическая композиция, предназначенная для лечения глазной болезни
BRPI0517799A (pt) composição para facilitar o parto humano
WO2013033074A3 (en) Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use
WO2013130953A3 (en) Autism-associated biomarkers and uses thereof
MX336280B (es) Metodos y composiciones para diagnosticos y pronosticos de lesion renal y falla renal.
WO2010090834A3 (en) Netrin-1 as a biomarker of injury and disease
WO2010138610A3 (en) Novel desmin phosphorylation sites useful in diagnosis and intervention of cardiac disease
WO2006026557A3 (en) Methods and kits for predicting risk for peterm labor
WO2007041283A3 (en) Maternal chelation for embryo, fetal, and infant benefit
WO2007109293A3 (en) Early diagnosis of congenital abnormalities in the offspring of diabetic mothers
WO2012024302A3 (en) Biomarkers of cancer
UA51718U (ru) Способ отбора беременных женщин с рубцом на матке для попытки влагалищных родов с определением статуса кандидата на дородовом и интранатальном этапах
RU2006129738A (ru) Способ прогнозирования восстановления эффективного деторождения после иммуноцитотерапии у женщин с невынашиванием беременности ранних сроков
WO2007044438A3 (en) Diagnosis and prevention of fetal heart disease

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights